International Survey Research Articles

Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries

Systemic lupus erythematosus (SLE) is characterised by increased cardiovascular morbidity and mortality risk. We aimed to examine the prevalence of traditional cardiovascular risk factors and their control in an international survey of patients with systemic lupus erythematosus. In this multicentre, cross-sectional study, cardiovascular risk factor data from medical files of adult patients (aged ≥18) with SLE followed between Jan 1, 2015, and Jan 1, 2020, were collected from 24 countries, across five continents. We assessed the prevalence and target attainment of cardiovascular risk factors and examined potential differences by country income level and antiphospholipid syndrome coexistence. We used the Systemic Coronary Risk Evaluation algorithm for cardiovascular risk estimation, and the European Society of Cardiology guidelines for assessing cardiovascular risk factor target attainment. People with lived experience were not involved in the research or writing process. 3401 patients with SLE were included in the study. The median age was 43·0 years (IQR 33-54), 3047 (89·7%) of 3396 patients were women, 349 (10.3%) were men, and 1629 (48·1%) of 3390 were White. 556 (20·7%) of 2681 patients had concomitant antiphospholipid syndrome. We found a high cardiovascular risk factor prevalence (hypertension 1210 [35·6%] of 3398 patients, obesity 751 [23·7%] of 3169 patients, and hyperlipidaemia 650 [19·8%] of 3279 patients), and suboptimal control of modifiable cardiovascular risk factors (blood pressure [target of <130/80 mm Hg], BMI, and lipids) in the entire SLE group. Higher prevalence of cardiovascular risk factors but a better blood pressure (target of <130/80 mm Hg; 54·9% [1170 of 2132 patients] vs 46·8% [519 of 1109 patients]; p<0·0001), and lipid control (75·0% [895 of 1194 patients] vs 51·4% [386 of 751 patients], p<0·0001 for high-density lipoprotein [HDL]; 66·4% [769 of 1158 patients] vs 60·8% [453 of 745 patients], p=0·013 for non-HDL; 80·9% [1017 of 1257 patients] vs 61·4% [486 of 792 patients], p<0·0001 for triglycerides]) was observed in patients from high-income versus those from middle-income countries. Patients with SLE with antiphospholipid syndrome had a higher prevalence of modifiable cardiovascular risk factors, and significantly lower attainment of BMI and lipid targets (for low-density lipoprotein and non-HDL) than patients with SLE without antiphospholipid syndrome. High prevalence and inadequate cardiovascular risk factor control were observed in a large multicentre and multiethnic SLE cohort, especially among patients from middle-income compared with high-income countries and among those with coexistent antiphospholipid syndrome. Increased awareness of cardiovascular disease risk in SLE, especially in the above subgroups, is urgently warranted. None.

An Archival Framework for Sharing of Cultural Heritage 3D Survey Data: OpenHeritage3D.org

Abstract. Photogrammetry and LiDAR have become increasingly accessible methods for documentation of Cultural Heritage sites. Academic and government agencies recognize the utility of high-resolution 3D models supporting long-term asset management through visualization, conservation planning, and change detection. Though detailed models can be created with increasing ease, their potential for future use can be constrained by a lack of accompanying topographic data, data collector skill level, and incomplete recording of the key metadata and paradata which make such survey data useful to future endeavors. In this paper, informed by various international survey organizations and data archives, we present a framework to record and communicate Cultural Heritage - focusing on architectures based on 3D metric survey - to first describe the data and metadata which should be included by surveyors to enable data usage and to communicate the expected utility of this data.

Use of levothyroxine for euthyroid, thyroid antibody positive women with infertility: Analyses of aggregate data from a survey of European thyroid specialists (Treatment of Hypothyroidism in Europe by Specialists: An International Survey).

The use of levothyroxine (LT4) treatment aiming to improve fertility in euthyroid women with positive thyroid peroxidase antibodies (TPOAb) is not supported by the available evidence. The aim of the study was to document the use of LT4 by European thyroid specialists in such patients. The data presented derive from Treatment of Hypothyroidism in Europe by Specialists, an International Survey (THESIS), a questionnaire conducted between 2019 and 2021 to document the management of hypothyroidism by European thyroid specialists. Here, we report the aggregate results on the use of LT4 in infertile, euthyroid women with positive TPOAb. A total of 2316/5406 (42.8%) respondents stated that LT4 may be indicated in TPOAb positive euthyroid women with infertility. The proportion of those replying positively to this question varied widely across different countries (median 39.4, range 22.9%-83.7%). In multivariate analyses males (OR: 0.8; CI: 0.7-0.9) and respondents >60 years (OR: 0.7; 0.6-0.8) were the least inclined to consider LT4 for this indication. Conversely, respondents managing many thyroid patients ("weekly" [OR: 1.4; CI: 1.0-1.9], "daily" [OR: 1.8; CI: 1.3-2.4]) and practicing in Eastern Europe (OR: 1.5; CI: 1.3-1.9) were most likely to consider LT4. A remarkably high number of respondents surveyed between 2019 and 2021, would consider LT4 treatment in TPOAb positive euthyroid women with infertility. This view varied widely across countries and correlated with sex, ageand workload, potentially influencing patient management. These results raise concerns about potential risks of overtreatment.

Do we really apply evidence-based-recommendations to spine surgery? Results of an international survey

ObjectiveThis international survey investigated Evidence-Based Medicine (EBM) in spine surgery by measuring its acceptance among spine surgeons. It assessed their understanding of EBM and how they apply it in practice by analyzing responses to various clinical scenarios..Materials and methodsFollowing the CHERRIES guidelines, an e-survey was distributed to multiple social media forums for neurosurgeons and orthopedic surgeons on Facebook, LinkedIn, and Telegram and circulated further through email via the authors’ network. Three hundred participants from Africa, Asia, Europe, North America, and Oceania completed the survey.ResultsOur study revealed that 67.7% (n = 203) of respondents used EBM in their practice, and 97.3% (n = 292) believed training in research methodology and EBM was necessary for the practice of spine surgery. Despite this endorsement of using EBM in spine surgery, we observed varied responses to how EBM is applied in practice based on example scenarios. The responders who had additional training tended to obey EBM guidelines more than those who had no additional training. Most surgeons responded as always or sometimes prescribing methylprednisolone to patients with acute spinal cord injury. Other significant differences were identified between geographical regions, training, practice settings, and other factors.ConclusionsMost respondents used EBM in practice and believed training in research methodology and EBM is necessary for spine surgery; however, there were significant variations on how to use them per case. Thus, the appropriate application of EBM in clinical settings for spinal surgery must be further studied.

Comparing STEM and Non-STEM Teachers’ Self-Efficacy in Multicultural Classrooms: Insights from TALIS 2018 U.S. Data

AbstractDrawing on U.S. data from the Teaching and Learning International Survey (TALIS) 2018, this study first compared STEM and non-STEM teachers’ self-efficacy in multicultural classrooms (TSMC), then identified the factors related to TSMC for each group of teachers, and lastly explored the similarities and differences among the factors. Results from general linear model univariate analysis revealed that STEM teachers scored significantly lower in TSMC than their non-STEM counterparts. Results from multilevel modeling analysis indicated that gender and professional development needs were significant predictors of TSMC for both groups; factors such as initial teacher preparation, professional development topics, and school instructional leadership emerged as significant predictors only for non-STEM teachers. The implications and significance of these results were discussed.

Beyond group comparisons: Accounting for intersectional sources of bias in international survey measures

International surveys are increasingly being used to understand nonacademic outcomes like math and science motivation, and to inform education policy changes within countries. Such instruments assume that the measure works consistently across countries, ethnicities, and languages—that is, they assume measurement invariance. While studies have already demonstrated that some items in international survey measures are noninvariant using basic group comparisons, they do not investigate complex, intersectional sources of bias that go beyond group membership. In this study, we use an emergent method to examine the sensitivity of item parameters from the Programme for International Student Assessment (PISA) survey instruments to intersectional sources of bias. Results indicate that non-invariance exists for most of the items examined, which can change individual scores after accounting for the moderators. Although country-level ranking did not change substantively after accounting for bias, policymaking is likely to be influenced negatively if such sources of non-invariance are not addressed.

Data analysis plan of the OECD PaRIS survey: leveraging a multi-level approach to analyse data collected from people living with chronic conditions and their primary care practices in 20 countries

ObjectiveIn view of the increasing number of people with (multiple) chronic conditions, the Organisation for Economic Co-operation and Development (OECD) initiated the International Survey of People Living with Chronic Conditions (PaRIS survey), which aims to provide insight in patient-reported outcomes and experiences of chronic care provided by primary care practices to support policy development. The objective of this research note is to describe the structure of the data, collected in the PaRIS survey and how the data will be analysed in a multilevel approach for cross-country comparison.Analysis planThe data structure of the PaRIS survey represents three levels: countries/health systems, primary care practices and patients. Multilevel analysis is used because of its accuracy in estimating country-level outcomes, its flexibility in modelling relationships, and its opportunities in connecting to relevant policy questions. Country-level outcomes will be estimated to facilitate cross-country comparison and (future) within-country comparison over time. Characteristics of patients that potentially explain variation in patient-reported outcomes and experiences can be linked to primary care practice and country/health system characteristics. This makes it possible to address policy-relevant questions relating, e.g., to the impact of chronic care management on patients with a specific chronic condition.

Patient care and access to clinical trials in gynaecological oncology: global implications of the early phase of the COVID-19 pandemic

PurposeOur prospective international survey evaluated the impact of the early phase of the COVID-19 pandemic on the management gynaecological malignancies from the multidisciplinary physicians’ perspective with particular focus on clinical infrastructures and trial participation.MethodsOur survey consisted of 53 COVID-related questions. It was sent to healthcare professionals in gynaecological oncology centres across Europe and Pan-Arabian region via the study groups and gynaecological societies from April 2020 to October 2020. All healthcare professionals treating gynaecological cancers were able to participate in our survey.ResultsA total of 255 answers were collected from 30 countries. The majority (73%) of participants were gynaecological oncologists from university hospitals (71%) with at least an Intensive Care Unit with cardiopulmonary support available at their institutions. Most institutions continued to perform elective surgeries only for oncological cases (98%). Patients had to wait on average 2 weeks longer for their surgery appointments compared to previous years (range 0–12 weeks). Most cases that were prioritised for surgical intervention across all gynaecological tumours were early-stage disease (74%), primary situation (61%) and good ECOG status (63%). The radicality of surgery did not change in the majority of cases (78%) across all tumour types. During the pandemic, only 38% of clinicians stated they would start a new clinical trial. Almost half of the participants stated the pandemic negatively impacted the financial structure and support for clinical trials. Approximately 20% of clinicians did not feel well-informed regarding clinical algorithm for COVID-19 patients throughout the pandemic. Thirty percent stated that they are currently having trouble in providing adequate medical care due to staff shortage.ConclusionDespite well-established guidelines, pandemic clearly affected clinical research and patientcare. Our survey underlines the necessity for building robust emergency algorithms tailored to gynaecological oncology to minimise negative impact in crises and to preserve access to clinical trials.

The IMPACT Survey: the economic impact of osteogenesis imperfecta in adults

BackgroundThe IMPACT survey aimed to elucidate the humanistic, clinical and economic burden of osteogenesis imperfecta (OI) on individuals with OI, their families, caregivers and wider society. Research methodology, demographics and initial insights from the survey have been previously reported. The cost of illness (healthcare resource use, productivity loss, out-of-pocket spending) and drivers of the economic impact of OI are reported here.MethodsIMPACT was an international mixed-methods online survey in eight languages (fielded July–September 2021) targeting adults (aged ≥ 18 years) or adolescents (aged ≥ 12–17 years) with OI, caregivers with or without OI and other close relatives. Survey domains included demographics, socioeconomic factors, clinical characteristics, treatment patterns, quality of life and health economics. The health economic domain for adults, which included questions on healthcare resource use, productivity loss and out-of-pocket spending, was summarised. Regression and pairwise analyses were conducted to identify independent drivers and associations with respondent characteristics.ResultsOverall, 1,440 adults with OI responded to the survey. Respondents were mostly female (70%) and from Europe (63%) with a median age of 43 years. Within a 12-month period, adults with OI reported visiting a wide range of healthcare professionals. Two-thirds (66%) of adults visited a hospital, and one-third (33%) visited the emergency department. The mean total number of diagnostic tests undergone by adults within these 12 months was 8.0. Adults had undergone a mean total of 11.8 surgeries up to the time point of the survey. The proportions of adults using queried consumables or services over 12 months ranged from 18–82%, depending on the type of consumable or service. Most adults (58%) were in paid employment, of which nearly one-third (29%) reported missing a workday. Of the queried expenses, the mean total out-of-pocket spending in 4 weeks was €191. Respondent characteristics such as female sex, more severe self-reported OI and the experience of fractures were often associated with increased economic burden.ConclusionIMPACT provides novel insights into the substantial cost of illness associated with OI on individuals, healthcare systems and society at large. Future analyses will provide insights into country-specific economic impact, humanistic impact and the healthcare journey of individuals with OI.

Delirium in the United States: Results From the 2023 Cross-Sectional World Delirium Awareness Day Prevalence Study

Delirium is an acute brain dysfunction associated with an increased risk of mortality and future dementia. To describe the prevalence of clinically documented delirium in the United States on World Delirium Awareness Day2023. This is a sub-analysis of a prospective, cross-sectional, online, international survey. All health care settings were eligible, with the exception of operating rooms and outpatient clinics. Health care clinicians, administrators, and researchers completed the survey. The primary outcome was the prevalence of clinically documented delirium at 8:00 a.m. and 8:00 p.m. on March 15, 2023. Secondary outcomes were related to health care delivery. Descriptive statistics are reported. Differences between unit types (non-intensive care unit vs intensive care unit) were examined for all outcomes. Ninety-one hospital units reported on 1318/1213 patients. The prevalence of clinically documented delirium was 16.4% (n= 216/1318) at 8:00 a.m. and 17.9% (n= 217/1213) at 8:00 p.m. (P=0.316) and significantly differed between age groups, reported discipline, unit, and hospital types. Significant differences were identified between non-intensive care unit and intensive care unit settings in the use of delirium-related protocols, nonpharmacologic and pharmacologic management, educational processes, and barriers to evidence-based delirium care. To our knowledge, this is the first epidemiologic survey of clinically documented delirium across two time points in the United States. Delirium remains a significant burden and challenge for health care systems. The high percentage of units using delirium management protocols suggests administrator and clinician awareness of evidence-based strategies for its detection and mitigation. We provide recommendations for future studies and quality improvement projects to improve clinical recognition and management of delirium.

Endovascular neurosurgery in Europe: an International Survey and future perspectives.

Recent advancements in neurosurgery have transformed patient care through minimally invasive procedures and led to a notable surge in endovascular treatments. However, the regulatory landscape governing these procedures across European countries varies, impacting treatment access and collaboration. This paper discusses the results of a survey on European legislation regarding endovascular neurosurgery, exploring current practices and speculating on the field's future. An e-mail survey was distributed to 41 European countries, targeting European member societies within the EANS. Thirty-seven completed questionnaires were returned, providing insights into neuroendovascular treatment legislation and restrictions. Legislation and certification varied across the surveyed countries, with only two countries prohibiting endovascular neurosurgery. Eight countries required specific fellowship programs. Resistance from radiologists was noted in many countries. Despite growing support for neurosurgeons performing endovascular treatments in Europe, challenges persist. Specialized care, improved access, and a broadening spectrum of treatable conditions contribute to the argument for involvement of neurosurgeons.

Concerns on digital health from a cardiac implantable electrical device remote monitoring clinic perspective: results from an international survey

Concerns on digital health from a cardiac implantable electrical device remote monitoring clinic perspective: results from an international survey

CSP2023: 426 - An international survey of experiences and attitudes towards Pacing using a heart rate monitor for people with ME / CFS

CSP2023: 426 - An international survey of experiences and attitudes towards Pacing using a heart rate monitor for people with ME / CFS

P330 Navigating the unknown: an international survey of current dietetic practices for overweight and obesity in people with cystic fibrosis

P330 Navigating the unknown: an international survey of current dietetic practices for overweight and obesity in people with cystic fibrosis

CSP2023: 449 - An international survey of experiences and attitudes towards Transauricular Vagus Nerve Stimulation for people with ME / CFS

CSP2023: 449 - An international survey of experiences and attitudes towards Transauricular Vagus Nerve Stimulation for people with ME / CFS

Test Maturity Model integration (TMMi): Test Maturity in the Financial Domain

Software quality is of utmost importance to the financial sector. Software testing plays a critical role in achieving software product quality. Financial institutions benefit from rigorous testing by having confidence in the reliability and performance of the software. This can lead to improved customer experience, increased operational efficiency, and reduced risks of system failures or security breaches. A questionnaire-based survey was designed and subsequently an international survey was conducted involving sixty financial institutions, e.g., banking, insurance companies and pension funds, from across the globe to understand their level of test maturity. As a reference framework against which to measure their test maturity, the Test Maturity Model integration (TMMi) was used. In this paper their motivations for doing test process improvement and the benefits they achieved are discussed. Concrete examples of the benefits achieved are provided. The role of test automation with test process improvement at the financial institutions is also reported upon in this paper. The most common level of test maturity achieved, measured against the TMMi, is TMMi level 3 “Defined” which represents a more than average level of test maturity. Benefits are reported by the financial institutions, especially in the areas of software quality and testing productivity. The benefits achieved show a high level of correlation with the motivations for investing in test process improvement. Almost all of financial institutions also use test automation to improve their testing in parallel with process improvement, with test automation at system level being by far the most popular.

Barriers and facilitators to vascular access point-of-care ultrasound in haemodialysis: An international survey of haemodialysis clinicians.

Utilising point-of-care ultrasound for assessment and cannulation of vascular access in people receiving haemodialysis has shown positive clinical results. Nonetheless, there is variation in how renal health care professionals worldwide embrace this method, and there's a lack of research on the factors that promote or hinder its adoption. To explore regional differences, and barriers and facilitators, to the use of point-of-care ultrasound for assessment and cannulation of vascular access in haemodialysis. Exploratory descriptive cross-sectional web-based survey. Healthcare clinicians working in haemodialysis responsible for cannulation of arteriovenous fistula or grafts. The survey was completed by 645 health care clinicians from 38 countries. 75% to 93% of respondents from Australia/New Zealand, Canada, Europe and United Kingdom/Ireland reported access to ultrasound, compared to 26% (n = 43/167) from the United States respondent's reported lower levels of ultrasound training than other regions. Facilitators for using ultrasound were: the availability of ultrasound training (87%, n = 558), to reduce miscannulations (76%, n = 255/336) and to improve patient outcomes (73%, n = 246/336). Point-of-care ultrasound barriers were lack of access to ultrasound education (82%, n = 196/239), lack of ultrasound machines (33%, n = 212/645) or believing that ultrasound was someone else's role (38%, n = 29/86). This study revealed national and regional differences related to haemodialysis point-of-care ultrasound. Understanding the regions requiring more education and implementation of ultrasound and what motivates staff, or deters from using ultrasound, is crucial for effectiveness of future implementation and workplace change initiatives.

Knowledge, attitudes and practices of using Indocyanine Green (ICG) fluorescence in emergency surgery: an international web-based survey in the ARtificial Intelligence in Emergency and trauma Surgery (ARIES)-WSES project.

Fluorescence imaging is a real-time intraoperative navigation modality to enhance surgical vision and it can guide emergency surgeons while performing difficult, high-risk surgical procedures. The aim of this study is to assess current knowledge, attitudes, and practices of emergency surgeons in the use of indocyanine green (ICG) in emergency settings. Between March 08, 2023 and April 10, 2023, a questionnaire composed of 27 multiple choice and open-ended questions was sent to 200 emergency surgeons who had previously joined the ARtificial Intelligence in Emergency and trauma Surgery (ARIES) project promoted by the WSES. The questionnaire was developed by an emergency surgeon with an interest in advanced technologiesand artificial intelligence. The response rate was 96% (192/200). Responders affirmed that ICG fluorescence can support the performance of difficult surgical procedures in the emergency setting, particularly in the presence of severe inflammation and in evaluating bowel viability. Nevertheless, there were concerns regarding accessibility and availability of fluorescence imaging in emergency settings. Eighty-seven out of 192 (45.3%) respondents have a fluorescence imaging system of vision for both elective and emergency surgical procedures; 32.3% of respondents have this system solely for elective procedures; 21.4% of respondents do not have this system, 15% do not have experience with it, and 38% do not use this imaging in emergency surgery. Less than 1% (2/192) affirmed that ICG fluorescence changed always their intraoperative decision-making. Precision surgery effectively tailors surgical interventions to individual patient characteristics using advanced technology, data analysis and artificial intelligence. ICG fluorescence can serve as a valid and safe tool to guide emergency surgery in different scenarios, such as intestinal ischemia and severe acute cholecystitis. Due to the lack of high-level evidence within this field, a consensus of expert emergency surgeons is needed to encourage stakeholders to increase the availability of fluorescence imaging systems and to support emergency surgeons in implementing ICG fluorescence in their daily practice.

THerapy Efficacy in Short or long-coupled idiopathic ventricular fibrillation: an International Survey (THESIS)

Abstract Background A recent review of 86 patients with short or long-coupled premature ventricular complex (SLC-PVC) initiating idiopathic ventricular fibrillation (IVF) found high success rate in arrhythmia control with quinidine (QND) (83%) or radiofrequency ablation (RFA) (70.8%). Purpose To compare the efficacy of QND vs. RFA therapy in a large patient cohort with SLC-IVF. Methods THESIS included 287 patients with SLC-IVF screened from 58 centers and 1 multicenter group in 22 countries across 4 continents. The study cohort included 146 (50.9%) males, aged 39+14 years at the time of IVF documentation. Therapy groups were defined according to the first therapy given. Therapy success was defined as no VF recurrence. Results Patients presented after aborted cardiac arrest, ICD shocks, syncope, aborted cardiac arrest + arrhythmic storm, arrhythmic storm, palpitations, seizures or were asymptomatic in 121 (42%), 51(18%), 42(14.6%), 27 (9.4%), 23 (8%), 8 (2.8%), 6 (2.1%) and 9 (3.1%), respectively. Fifty-three patients (18.5%) had a prior history of syncope. Eleven (3.8%) patients required ECMO support. Mean shortest and longest coupling interval which triggered VF in the same patient were 304.9+82ms and 341.2+94.1ms, respectively. VF initiation with "long" coupled PVC (coupling interval &amp;gt;350ms) was observed in 41 (18.1%) patients, and VF initiation with both short and long coupled PVC was documented in 30 (13.2%) others. RFA was performed in 112 patients and QND was given to 68 patients. Patients were followed during a mean follow-up of 84.8+64.5 months. Therapy success was achieved in the RFA or QND group in 69 (62.2%) and 49 (71%) patients, respectively (p=0.29). The RV Purkinje was the main targeted ablation site in 46 (47.4%) patients. Treatment success varied according to the site of origin (SOO) of the PVC which triggered VF. Therapy success was higher with QND when PVC SOO based on ECG, was the RV inflow tract (81.3% vs. 57.7%, p=0.048) or when the SOO was not available (67.9% vs 36.4%, p=0.064), and when the coupling interval/QT ratio was &amp;lt;1 (75.5% vs. 57.5%, p=0.03), Figures 1,2. A higher success rate with ablation compared with QND was seen with LV- SOO compared with RV-SOO (82.1% vs 60.3%, p=0.019). Similarly, successful ablation was achieved in 83.3% (n=24) vs. 55.9% (n=68) patients with LV and RV-SOO respectively; p=0.004. One patient expired of sudden cardiac death due to misdiagnosis, while wearing a subcutaneous -ICD, without any drug or ablation therapy. Conclusions SLC-IVF strikes males and females equally. SLC-PVCs triggering the arrhythmia mainly arise from the RV Purkinje system. QND and RFA have similar efficacy in arrhythmia control. Quinidine has a higher treatment success rate in patients with PVC-SOO in the RV inflow area and in those with coupling interval/QT&amp;lt;1.Figure 1Treatment success by SOOFigure 2Treatment success by CI/QT

Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey.

Background/Objectives: The development of biosimilar drugs has revolutionized the management of patients with inflammatory bowel diseases (IBD), significantly reducing healthcare costs. However, the impact of biosimilar availability on patient care is unknown. We conducted a survey to investigate the benefits of using biosimilars in patients with IBD. Methods: Physicians involved in the IBD care were invited to participate in an anonymous online survey. The questionnaire consisted of 42 questions addressing availability, cost, recommendations, and positioning regarding the use of biosimilars. Results: A total of 233 physicians (88.4% gastroenterologists) from 63 countries worldwide participated in the survey. Most respondents had >10 years of practice (202/233, 85.9%). Biosimilars were available in almost all cases (221, 94.8%), and over two-thirds of respondents had more than one biosimilar of adalimumab or infliximab on hospital formulary. In most cases, adalimumab and infliximab biosimilars had a reduced cost of at least 30% compared to the originators. The savings resulting from the use of biosimilars allowed physicians to improve patient care (3/233, 1.3%) or to improve research (2/233, 0.8%) in only a few cases. Interestingly, for about 50% of respondents, the cost of biologics was a limitation for patient access to therapy. For the majority of participants, the availability of biosimilars did not influence treatment decisions in Crohn's disease (70/165, 42.4%) and ulcerative colitis (83/165, 50.3%). Conclusions: The reduced cost of biosimilars compared to reference products is the main driver of choice in IBD. The impact of biosimilars of ustekinumab and vedolizumab in improving access to therapies and changing the treatment algorithm remains to be defined.